Last reviewed · How we verify
NCT04018118: COHESION
Study of Clinical Profiles of Patients Followed for Chronic Hypereosinophilia and/or Hypereosinophilic Syndrome by the Creation of a National Cohort
trial testing Biological sample in Eosinophilia in 600 participants. Currently enrolling.
6 May 2029
Quick facts
| Lead sponsor | University Hospital, Lille |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 600 |
| Start date | 6 May 2019 |
| Primary completion | 6 May 2029 |
| Estimated completion | 1 May 2031 |
| Sites | 1 location across France |
Drugs / interventions tested
- Biological sample — full drug profile →
Conditions studied
- Eosinophilia — all drugs for Eosinophilia →
- Hypereosinophilic Syndrome — all drugs for Hypereosinophilic Syndrome →
Sponsor
University Hospital, Lille
Who can join
Eligibility, any sex, with Eosinophilia or Hypereosinophilic Syndrome. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Frequency of the different clinical manifestations at time of diagnosis and during follow-up of the hypereosinophilic syndrome (HES)
Time frame: 10 years
The primary objective of the study is to describe the frequency of the different clinical manifestations at diagnosis and during follow-up of the hypereosinophilic syndrome (HES/HE). The primary endpoint is the frequency of the different clinical manifestations and/or organs damage related to hypereosinophilia.
Sponsor's own description
Unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES) are heterogeneous regarding the organ involvements (heart, lungs, skin, .. or none), the evolutionary profiles, the response to treatments. Underlying mechanisms are largely unknown and may associate genetic predisposing factors (germinal ? somatic?), environmental factors (alimentation, tobacco use, hormones, infections, ..) The COHESion study aims to study all clinical and biological characteristics of HE/HES patients and their evolutionary profiles, with a focus on genetic factors and the mechanisms supporting transitory or persistant chronic HE/HES (in absence of any well identified extrinsic trigger like drugs, parasitosis, ..)
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The multidisciplinary approach to eosinophilia.
Thomsen GN, Christoffersen MN, Lindegaard HM, Davidsen JR, et al · · 2023 · cited 21× · PMID 37274287 · DOI 10.3389/fonc.2023.1193730 -
Hypereosinophilia and Hypereosinophilic Syndromes: First Findings From a Nationwide Multicenter Cohort.
Lefèvre G, Bleuse S, Puyade M, Moulis G, et al · · 2025 · cited 11× · PMID 39757773 · DOI 10.1111/all.16463
Verify or expand the search:
- PubMed search for NCT04018118
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biological sample
Trials testing the same drug.
- NCT03098238 — Endothelial Microparticules and Antibody Mediated Rejection and Kidney Transplantation: Biomarker of Antibody-mediated R · NA · completed
- NCT03797053 — Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology · unknown
Other recruiting trials for Eosinophilia
Currently open trials in the same condition.
- NCT06265870 — Specific Versus Empirical Anthelminthic Treatment in Eosinophilia · NA · recruiting
- NCT05942222 — A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis Wit · Phase 4 · active not recruiting
- NCT03801434 — Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders · Phase 2 · recruiting
- NCT00091871 — A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression · recruiting
- NCT00001406 — Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia · recruiting
Other University Hospital, Lille trials
Trials by the same sponsor.
- NCT07528664 — Assessement of a Test a Financial-incentive Program for Pregnant Women and Their Smoking Partners to Reduce Smoking Duri · NA · not yet recruiting
- NCT07434739 — PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies · NA · not yet recruiting
- NCT06958224 — Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers · NA · not yet recruiting
- NCT07408999 — Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer · NA · not yet recruiting
- NCT07492030 — Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04018118 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Lille
- Last refreshed: 18 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04018118.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing